Sight Sciences (SGHT) Projected to Post Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is projected to post its quarterly earnings results after the market closes on Wednesday, March 5th. Analysts expect Sight Sciences to post earnings of ($0.22) per share and revenue of $18.98 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Sight Sciences Price Performance

Shares of NASDAQ SGHT opened at $2.51 on Tuesday. Sight Sciences has a twelve month low of $2.29 and a twelve month high of $8.45. The firm has a market cap of $127.40 million, a P/E ratio of -2.46 and a beta of 2.52. The company has a 50 day moving average of $2.99 and a 200 day moving average of $4.49. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36.

Analysts Set New Price Targets

A number of brokerages have weighed in on SGHT. Stifel Nicolaus decreased their target price on shares of Sight Sciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, February 6th. Citigroup decreased their target price on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Morgan Stanley decreased their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Piper Sandler reiterated a “neutral” rating and set a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Finally, Lake Street Capital decreased their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, January 15th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.68.

Insider Activity

In other news, CEO Paul Badawi sold 12,236 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total transaction of $44,049.60. Following the completion of the sale, the chief executive officer now owns 5,713,197 shares of the company’s stock, valued at $20,567,509.20. The trade was a 0.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 63,014 shares of company stock valued at $197,295 in the last 90 days. Company insiders own 28.90% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.